
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4983149/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interaction of the Fanconi Anemia Proteins and BRCA1 in a Common Pathway. Molecular Cell, 2001, 7, 249-262.	9.7	1,125
2	Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes and Development, 2005, 19, 489-501.	5.9	1,122
3	53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Structural and Molecular Biology, 2010, 17, 688-695.	8.2	846
4	X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell, 2006, 9, 121-132.	16.8	736
5	BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function. Cell, 2001, 105, 149-160.	28.9	606
6	Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i> -Mutated Mouse Mammary Tumors. Cancer Discovery, 2013, 3, 68-81.	9.4	428
7	Genetic Analysis of BRCA1 Function in a Defined Tumor Cell Line. Molecular Cell, 1999, 4, 1093-1099.	9.7	332
8	The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8222-8227.	7.1	332
9	Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. Journal of Clinical Investigation, 2016, 126, 2334-2340.	8.2	312
10	Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nature Genetics, 2000, 26, 85-88.	21.4	297
11	BRCA1 Supports XIST RNA Concentration on the Inactive X Chromosome. Cell, 2002, 111, 393-405.	28.9	283
12	Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes and Cancer, 2010, 1, 152-163.	1.9	283
13	BMI1 Is Recruited to DNA Breaks and Contributes to DNA Damage-Induced H2A Ubiquitination and Repair. Molecular and Cellular Biology, 2011, 31, 1972-1982.	2.3	220
14	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nature Reviews Clinical Oncology, 2021, 18, 773-791.	27.6	198
15	High Expression of Lymphocyte-Associated Genes in Node-Negative HER2+ Breast Cancers Correlates with Lower Recurrence Rates. Cancer Research, 2007, 67, 10669-10676.	0.9	190
16	Expectation–Maximization-Driven Geodesic Active Contour With Overlap Resolution (EMaGACOR): Application to Lymphocyte Segmentation on Breast Cancer Histopathology. IEEE Transactions on Biomedical Engineering, 2010, 57, 1676-1689.	4.2	171
17	Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. Journal of the National Cancer Institute, 2018, 110, 316-320.	6.3	171
18	Mutational Landscape of the Essential Autophagy Gene <i>BECN1</i> in Human Cancers. Molecular Cancer Research, 2014, 12, 485-490.	3.4	167

#	Article	IF	CITATIONS
19	Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. International Journal of Molecular Sciences, 2016, 17, 2113.	4.1	165
20	PALB2 Interacts with KEAP1 To Promote NRF2 Nuclear Accumulation and Function. Molecular and Cellular Biology, 2012, 32, 1506-1517.	2.3	164
21	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist, 2016, 21, 762-770.	3.7	119
22	Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes and Development, 2001, 15, 1188-1193.	5.9	118
23	Autophagy Opposes p53-Mediated Tumor Barrier to Facilitate Tumorigenesis in a Model of <i>PALB2</i> -Associated Hereditary Breast Cancer. Cancer Discovery, 2013, 3, 894-907.	9.4	118
24	The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. Cell Reports, 2015, 13, 1895-1908.	6.4	117
25	The disappearing Barr body in breast and ovarian cancers. Nature Reviews Cancer, 2007, 7, 628-633.	28.4	112
26	Active Localization of the Retinoblastoma Protein in Chromatin and Its Response to S Phase DNA Damage. Molecular Cell, 2003, 12, 735-746.	9.7	110
27	Multi-Field-of-View Framework for Distinguishing Tumor Grade in ER+ Breast Cancer From Entire Histopathology Slides. IEEE Transactions on Biomedical Engineering, 2013, 60, 2089-2099.	4.2	104
28	Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. JCO Precision Oncology, 2020, 4, 442-465.	3.0	103
29	Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. Journal of Clinical Investigation, 2012, 122, 1920-1932.	8.2	101
30	High-throughput adaptive sampling for whole-slide histopathology image analysis (HASHI) via convolutional neural networks: Application to invasive breast cancer detection. PLoS ONE, 2018, 13, e0196828.	2.5	100
31	Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers. Laboratory Investigation, 2018, 98, 1438-1448.	3.7	99
32	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.	1.6	96
33	BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. Journal of Molecular Cell Biology, 2011, 3, 66-74.	3.3	91
34	RET rearrangements are actionable alterations in breast cancer. Nature Communications, 2018, 9, 4821.	12.8	87
35	Association of Nuclear Localization of a Long Interspersed Nuclear Element-1 Protein in Breast Tumors with Poor Prognostic Outcomes. Genes and Cancer, 2010, 1, 115-124.	1.9	76
36	Further Evidence for BRCA1 Communication with the Inactive X Chromosome. Cell, 2007, 128, 991-1002.	28.9	72

#	Article	IF	CITATIONS
37	Emerging strategies for treating metastasis. Nature Cancer, 2021, 2, 258-270.	13.2	71
38	Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer. BMC Cancer, 2018, 18, 610.	2.6	67
39	Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. Nature Cancer, 2020, 1, 923-934.	13.2	67
40	Male Fertility Defect Associated with Disrupted BRCA1-PALB2 Interaction in Mice. Journal of Biological Chemistry, 2014, 289, 24617-24629.	3.4	65
41	Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. Oncologist, 2016, 21, 1315-1325.	3.7	64
42	Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine. Frontiers in Oncology, 2017, 7, 2.	2.8	63
43	Role of Biomarkers in the Development of PARP Inhibitors. Biomarkers in Cancer, 2016, 8s1, BIC.S36679.	3.6	57
44	Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood, 2018, 131, 2501-2505.	1.4	57
45	BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma. Clinical Cancer Research, 2017, 23, 5631-5638.	7.0	56
46	Tripartite Motif-containing 33 (TRIM33) Protein Functions in the Poly(ADP-ribose) Polymerase (PARP)-dependent DNA Damage Response through Interaction with Amplified in Liver Cancer 1 (ALC1) Protein. Journal of Biological Chemistry, 2013, 288, 32357-32369.	3.4	53
47	Surveillance nanotechnology for multi-organ cancer metastases. Nature Biomedical Engineering, 2017, 1, 993-1003.	22.5	51
48	A 2D mechanistic model of breast ductal carcinoma in situ (DCIS) morphology and progression. Journal of Theoretical Biology, 2010, 263, 393-406.	1.7	47
49	Biomarkers for Immunotherapy: Current Developments and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e493-e503.	3.8	41
50	Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer. Molecular Cancer Research, 2009, 7, 1487-1496.	3.4	40
51	Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. Gynecologic Oncology, 2016, 141, 2-9.	1.4	40
52	PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response. Oncogene, 2019, 38, 1585-1596.	5.9	39
53	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Research and Treatment, 2017, 162, 597-602.	2.5	38
54	ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic <i>Becn1</i> loss. Autophagy, 2014, 10, 662-676.	9.1	36

#	Article	IF	CITATIONS
55	Roadmap to a Comprehensive Clinical Data Warehouse for Precision Medicine Applications in Oncology. Cancer Informatics, 2017, 16, 117693511769434.	1.9	36
56	Amplified Loci on Chromosomes 8 and 17 Predict Early Relapse in ER-Positive Breast Cancers. PLoS ONE, 2012, 7, e38575.	2.5	33
57	Triple-negative breast cancer. Current Opinion in Obstetrics and Gynecology, 2014, 26, 34-40.	2.0	33
58	IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5 ⁺ B― and Tâ€cell trafficking to tumorâ€conditioned media. Immunology and Cell Biology, 2015, 93, 486-499.	2.3	33
59	Towards Improved Cancer Diagnosis and Prognosis Using Analysis of Gene Expression Data and Computer Aided Imaging. Experimental Biology and Medicine, 2009, 234, 860-879.	2.4	32
60	Biomarkers for Response to Immune Checkpoint Blockade. Annual Review of Cancer Biology, 2020, 4, 331-351.	4.5	29
61	Nuclear topology modulates the mutational landscapes of cancer genomes. Nature Structural and Molecular Biology, 2017, 24, 1000-1006.	8.2	28
62	Protein-lysine methyltransferases G9a and GLP1 promote responses to DNA damage. Scientific Reports, 2017, 7, 16613.	3.3	28
63	Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers. Genes and Cancer, 2010, 1, 1063-1073.	1.9	27
64	Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells. Breast Cancer Research and Treatment, 2015, 151, 57-73.	2.5	27
65	Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. Biomarkers in Cancer, 2016, 8s1, BIC.S34417.	3.6	27
66	A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. Journal of Thoracic Oncology, 2019, 14, 1982-1988.	1.1	27
67	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. Oncology, 2020, 98, 905-912.	1.9	27
68	ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers. PLoS ONE, 2012, 7, e30447.	2.5	26
69	MYC, PARP1, and Chemoresistance: BIN There, Done That?. Science Signaling, 2011, 4, pe15.	3.6	25
70	Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum. JCO Precision Oncology, 2018, 2, 1-4.	3.0	23
71	Genomic and immunologic correlates of LAG-3 expression in cancer. Oncolmmunology, 2020, 9, 1756116.	4.6	22
72	Metabotropic Glutamate Receptor 1 Expression and Its Polymorphic Variants Associate with Breast Cancer Phenotypes. PLoS ONE, 2013, 8, e69851.	2.5	22

#	Article	IF	CITATIONS
73	The DNA repair function of <i>CUX1</i> contributes to radioresistance. Oncotarget, 2017, 8, 19021-19038.	1.8	21
74	Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells. Oncotarget, 2017, 8, 44639-44653.	1.8	20
75	Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	16
76	A hybrid approach to modeling the dynamics of macromolecules. Journal of Chemical Physics, 1986, 85, 3655-3673.	3.0	14
77	<i>ERG</i> and <i>CHD1</i> heterogeneity in prostate cancer: Use of confocal microscopy in assessment of microscopic foci. Prostate, 2014, 74, 1551-1559.	2.3	13
78	The Pan ancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist, 2020, 25, e39-e47.	3.7	13
79	All-FIT: allele-frequency-based imputation of tumor purity from high-depth sequencing data. Bioinformatics, 2020, 36, 2173-2180.	4.1	13
80	Tissue- and development-stage–specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples. Nucleic Acids Research, 2020, 48, 7079-7098.	14.5	12
81	A Novel Role of Chromodomain Protein CBX8 in DNA Damage Response. Journal of Biological Chemistry, 2016, 291, 22881-22893.	3.4	11
82	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker. Biomarker Insights, 2022, 17, 117727192210787.	2.5	11
83	Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib. European Urology, 2015, 67, 353-354.	1.9	10
84	Evidence of Intertissue Differences in the DNA Damage Response and the Pro-oncogenic Role of NF-κB in Mice with Disengaged BRCA1–PALB2 Interaction. Cancer Research, 2018, 78, 3969-3981.	0.9	10
85	Gene expression of adipokines and adipokine receptors in the tumor microenvironment: associations of lower expression with more aggressive breast tumor features. Breast Cancer Research and Treatment, 2021, 185, 785-798.	2.5	10
86	Breast cancer among Asian Indian and Pakistani Americans: A surveillance, epidemiology and end resultsâ€based study. International Journal of Cancer, 2021, 148, 1598-1607.	5.1	10
87	Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing. JCO Precision Oncology, 2021, 5, 1749-1757.	3.0	10
88	Association of <i>JAK2</i> -V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms. JAMA Oncology, 2019, 5, 265.	7.1	9
89	SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis. Oncogene, 2021, 40, 6034-6048.	5.9	9
90	Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer. Case Reports in Oncology, 2021, 14, 931-937.	0.7	8

#	Article	IF	CITATIONS
91	Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial. ELife, 0, 11, .	6.0	8
92	Yin and yang of 4E-BP1 in cancer. Cell Cycle, 2016, 15, 1401-1402.	2.6	7
93	Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes. Cancer Treatment and Research Communications, 2020, 25, 100232.	1.7	7
94	Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer. Frontiers in Genetics, 2021, 12, 706435.	2.3	7
95	Precision Medicine: Implications for Science and Practice. Journal of the American College of Surgeons, 2016, 223, 433-439e1.	0.5	6
96	Poly (ADP-Ribose) Polymerase Inhibitor Activity in Prostate Cancers Harboring Mutations in DNA Repair Genes: Who Benefits?. JCO Precision Oncology, 2020, 4, 1034-1037.	3.0	6
97	Receptor-Defined Breast Cancer in Five East African Countries and Its Implications for Treatment: Systematic Review and Meta-Analysis. JCO Global Oncology, 2021, 7, 289-301.	1.8	6
98	Triple-negative breast cancers and the human mammary epithelial cell hierarchy. Breast Disease, 2011, 32, 49-61.	0.8	2
99	Clinicopathologic Presentation of Asian-Indian American (AIA) Women with Stage 0, I & II Breast Cancer. Journal of Immigrant and Minority Health, 2011, 13, 42-48.	1.6	2
100	Multiple primary malignancies in patients with anal squamous cell carcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 853-857.	1.4	2
101	A Quasi Birth-and-Death model for tumor recurrence. Journal of Theoretical Biology, 2019, 480, 175-191.	1.7	2
102	Gene Expression in Barrett's Esophagus Cell Lines Resemble Esophageal Squamous Cell Carcinoma Instead of Esophageal Adenocarcinoma. Cancers, 2021, 13, 5971.	3.7	2
103	Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100477.	3.0	2
104	Next Generation Sequencing As an Aid to Diagnosis and Treatment of an Unusual Pediatric Brain Cancer. Journal of Personalized Medicine, 2014, 4, 402-411.	2.5	0
105	Reply to T. Ménard. JCO Precision Oncology, 2022, , .	3.0	0